Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8229575 | 1.00 | L3MBTL1 (0.43) | L3MBTL1CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL8238261 | 0.98 | L3MBTL1 (0.39) | L3MBTL1CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL8235469 | 0.98 | L3MBTL1 (0.39) | L3MBTL1CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL8229576 | 0.98 | L3MBTL1 (0.44) | L3MBTL1CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL8229572 | 0.92 | L3MBTL1 (0.38) | L3MBTL1CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL8237938 | 0.88 | L3MBTL1 (0.37) | L3MBTL1CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL22389997 | 0.79 | L3MBTL1 (0.46) | L3MBTL1 | |
| SCHEMBL214038 | 0.79 | L3MBTL1 (0.46) | L3MBTL1 | |
| SCHEMBL939664 | 0.79 | L3MBTL1 (0.46) | L3MBTL1 | |
| SCHEMBL789155 | 0.79 | L3MBTL1 (0.46) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006083508-A2 | COMBINATIONS OF SUPEROXIDE DISMUTASE MIMETICS AND NONSTEROIDAL ANALGESIC/ANTI-INFLAMMATORY DRUGS | METAPHORE PHARMACEUTICALS INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20050171198-A1 | SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease | METAPHORE PHARMACEUTICALS, INC. | 2005-08-04 | — | — | US | disclosed |
| US-20050171198-A1 | SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease | METAPHORE PHARMACEUTICALS, INC. | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171198-A1 | SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease | SOD1, MPO, SOD3 | L3MBTL1 3171/4885CYP2C9 2701/4885TSHR 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.